Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-142 · 1 trial · 1 indication
FVC is a test that measures the total amount of air a person can fully exhale from their lungs after a deep inhalation. A low FVC can demonstrate reduced lung capacity.
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.
| Arm | Type | Description |
|---|---|---|
| Substudy 1: ABBV-142 | EXPERIMENTAL | Participants will receive ABBV-142 for 52 week during double-blind treatment period. Eligible participants may receive ABBV-142 for 52 weeks during open-label treatment period. |
| Substudy 1: Placebo for ABBV-142 | PLACEBO_COMPARATOR | Participants will receive placebo for ABBV-142 for 52 week during double-blind treatment period. Eligible participants may receive ABBV-142 for 52 weeks during open-label treatment period. |
| Name | Type | Description |
|---|---|---|
| ABBV-142 | DRUG | ABBV-142 |
| Placebo for ABBV-142 | DRUG | Placebo for ABBV-142 |
Inclusion Criteria: \- Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) within 7 years prior to screening, confirmed by the investigator at screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained within 12 months of the screening visit and verificatio...
Top 15 of 17 competitors
ABBV-142 is an investigational small molecule drug being developed by AbbVie Inc. for the treatment of idiopathic pulmonary fibrosis, a chronic and progressive lung disease. It is currently in Phase 2 clinical development and has not been approved by the FDA. It is being studied in a randomized, double-blind, placebo-controlled trial.
ABBV-142 is being studied for the treatment of idiopathic pulmonary fibrosis in adults. The Phase 2 trial enrolls participants aged 40 years and older and evaluates adverse events and change in disease activity. ABBV-142 is investigational and has not been approved for any indication.
ABBV-142 is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the Phase 2 clinical program evaluating ABBV-142 in idiopathic pulmonary fibrosis.
ABBV-142 is in Phase 2 clinical development. It is investigational and has not received FDA approval. The Phase 2 study is currently recruiting participants and is designed as a randomized, double-blind, placebo-controlled trial.
ABBV-142 is being evaluated in one Phase 2 clinical trial, NCT07230288, titled a study of ABBV-142 to assess adverse events and change in disease activity in adult participants with idiopathic pulmonary fibrosis. The trial is recruiting, has an enrollment of 165 participants, and is being conducted across the United States, Australia, Bulgaria, Canada, France, Germany, Greece, Japan, Poland, Portugal, Serbia, South Africa, South Korea, Spain, Taiwan, Turkey, and the United Kingdom.